



Substitute Information Disclosure Statement PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
13407-026US1Application No.  
10/538,823**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Elixir Pharmaceuticals, Inc.Filing Date  
June 13, 2005Group Art Unit  
1656**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AI	WO 98/58541	12/30/1998	PCT	G01N33	53		
	AJ							
	AK							
	AL							
	AM							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AN	Cheong et al., "Induction of Apoptosis by Apicidin, a Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways", Cancer Biology & Therapy (United States). September-October 2003, Vol. 2, No. 5, pages 544-551, entire document.
	AO	Marques et al., "Hemeptide Models for Hemoproteins: the Behavior of N-acetylmicroperoxidase-11 in Aqueous Solution", Journal Inorganic Biochemistry 75:281-291, 1999, entire document.
	AP	Rieder et al., "The Cytochrome C Oxidase Binding Site on Cytochrome C: Differential Chemical Modification of Lysine Residues in Free and Oxidase-Bound Cytochrome C", Journal Biological Chemistry 253:6045-6053, September 10, 1978, entire document.
	AQ	Yu et al., "Induction of Apoptosis in BCR/ABL+ Cells by Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways", Cancer Biology & Therapy (United States), 2:544-552, September-October 2003, entire document.

Examiner Signature /Jae W. Lee/ (07/16/2008)	Date Considered 07/16/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JWL/